Floatz logo

Ramelteon

Circadian Dysregulation

Massachusetts General HospitalSmall moleculeN/ADormant
D
24/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
9/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Circadian Dysregulation cohort.

Asset / SponsorPhaseRating
MELATONIN
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Phase 4BB
PROPOFOL
Nyree Penn
Phase 1CC
ZOLPIDEM
Massachusetts General Hospital
N/AD

Same molecule, other indications

Ramelteon is also rated in:

insomniaDormant
CCC
Indicative ·
53 / 100
View asset →
bipolar disorderDormant
CCC
Indicative ·
51 / 100
View asset →
migraine disorderDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →